Mode
Text Size
Log in / Sign up

Sabin-derived inactivated poliovirus vaccine shows comparable safety to conventional IPV in adult booster recipientsNew polio booster vaccine shows similar safety to current one

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that sIPV demonstrates a safety profile comparable to conventional IPV in adult booster recipients.

This meta-analysis evaluated the safety of Sabin-derived inactivated poliovirus vaccine (sIPV) compared to conventional IPV, w-IPV, or placebo in adult booster recipients across 4 trials. The analysis pooled data from 70 to 340 adults to assess local and systemic reactions.

The meta-analysis found no statistically significant differences between sIPV and comparators for several adverse events. Specifically, results for pain (RR 1.57, 95% CI 0.98 to 2.50), erythema (RR 1.54, 95% CI 0.64 to 3.69), induration (RR 0.33, 95% CI 0.04 to 3.06), fever (RR 0.96, 95% CI 0.39 to 2.33), headache (RR 0.70, 95% CI 0.21 to 2.37), and malaise (RR 0.75, 95% CI 0.17 to 3.27) all showed no significant differences. Adverse events were described as mild, transient, and comparable across vaccines, with most trials reporting no serious adverse events.

The authors noted limitations including small sample sizes and imprecision, leading to a low to very low certainty of evidence. Despite these limitations, the findings suggest sIPV has a favorable safety profile and may serve as a viable alternative in polio eradication strategies. Clinical application should be interpreted with caution due to the underlying data limitations.

How this fits prior evidence

This meta-analysis extends the evidence regarding the safety of Sabin-strain inactivated poliovirus vaccine (sIPV). While a previous finding confirmed that sIPV provides immunogenicity comparable to Salk-strain inactivated poliovirus vaccine with an acceptable safety profile for infants, this study specifically addresses the safety profile of sIPV in adult booster recipients. The current findings confirm that sIPV maintains a comparable safety profile to conventional IPV in adults, supporting its use in broader eradication strategies.

Getting a booster shot is never fun, especially if you worry about side effects. But a new option for polio boosters might put your mind at ease. A fresh look at four trials found that a newer vaccine, called Sabin-derived inactivated polio vaccine (sIPV), causes similar reactions as the conventional vaccine (cIPV) in adults. That means no more pain, redness, or fever than what you might already expect.

The analysis pooled results from 70 to 340 adults across four trials. It compared sIPV to the standard vaccine or a placebo. The researchers tracked common side effects like pain at the injection site, redness, swelling, fever, headache, and tiredness. For every one of these, the difference between the two vaccines was not statistically significant. In plain terms, the numbers could easily be due to chance, so the vaccines look comparable.

Serious side effects were rare. Most trials reported none at all. When side effects did occur, they were mild and short-lived. That's reassuring for adults who need a booster, especially as health officials work to wipe out polio for good.

Still, this evidence isn't rock solid. The trials were small, and the quality of the evidence is low to very low. So while sIPV seems like a fine choice, we need more research to be fully confident. If you're due for a booster, talk to your doctor about which vaccine is right for you.

What this means for you:
A newer polio booster vaccine appears just as safe as the standard one for adults, based on limited evidence.

Common questions

Is the new polio booster vaccine (sIPV) safe?

Based on a review of four trials with 70 to 340 adults, sIPV appears to have a safety profile similar to the conventional polio vaccine. Side effects like pain, redness, and fever were mild and short-lived. Most trials reported no serious side effects. However, the evidence is low to very low quality due to small sample sizes.

What side effects can I expect from the sIPV booster?

The most common side effects tracked were pain at the injection site, redness, swelling, fever, headache, and tiredness. None of these occurred significantly more often with sIPV than with the standard vaccine. When they did happen, they were mild and went away quickly. Serious side effects were rare or absent in the trials.

How does sIPV compare to the standard polio vaccine?

In the trials, sIPV and the conventional vaccine (cIPV) produced similar rates of side effects. For example, the risk of pain was about 1.57 times higher with sIPV, but this difference was not statistically significant, meaning it could be due to chance. The same was true for redness, swelling, fever, headache, and tiredness.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
Poliomyelitis remains a public health concern in select regions. Sabin strain-derived inactivated poliovirus vaccine (sIPV) offers a potentially safer and cost-effective alternative to conventional IPV (cIPV) for adult booster immunization. To systematically review and meta-analyze evidence on the safety of sIPV in adults. We searched PubMed, Embase, Cochrane, and Scopus through January 2026 for randomized controlled trials comparing sIPV with cIPV/w-IPV or placebo in adults. Safety outcomes included local and systemic adverse events: pain, erythema, induration, fever, headache, malaise, and allergic reactions. Data extraction and risk of bias assessment were independently performed. Meta-analysis was conducted using random-effects models in RevMan 5.4, reporting risk ratios (RR) with 95% confidence intervals (CI). Evidence certainty was assessed using GRADE. Four trials encompassing 70–340 adults were included. Pooled analyses demonstrated no statistically significant differences in any adverse events between sIPV and cIPV: pain (RR 1.57, 95% CI 0.98–2.50), erythema (RR 1.54, 95% CI 0.64–3.69), induration (RR 0.33, 95% CI 0.04–3.06), fever (RR 0.96, 95% CI 0.39–2.33), headache (RR 0.70, 95% CI 0.21–2.37), and malaise (RR 0.75, 95% CI 0.17–3.27). Heterogeneity was negligible (I2 = 0%). Overall, adverse events were mild, transient, and comparable across vaccines and most included trials reported no serious adverse events (SAEs), indicating a favorable safety profile. Certainty of evidence was low to very low due to small sample sizes and imprecision. sIPV demonstrates a safety profile comparable to conventional IPV in adult booster recipients, supporting its use as a viable alternative in polio eradication strategies. Further large-scale and long-term studies are warranted to confirm these findings.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.